STERIS (STE) Q3 2026: Tariff Impact Rises $10M as Service Outpaces Capital, Margin Pressures Persist
Tariff headwinds intensified for STERIS in Q3 2026, yet the company maintained high single-digit organic growth, underpinned by robust service momentum and resilient capital backlogs. Margin compression remains a central theme, with inflation and tariffs offsetting productivity gains. Investors should focus on STERIS’s ability to protect profitability and absorb rising input costs as it navigates the remainder of fiscal 2026 and plans for 2027.
Summary
- Tariff Headwinds Escalate: STERIS absorbed a sharp increase in tariff costs, pressuring margins despite strong revenue.
- Service Growth Offsets Capital Volatility: Recurring service and consumables demand continues to underpin segment stability.
- Margin Management in Focus: Cost mitigation and pricing discipline are critical as inflation and tariffs persist into next year.
Business Overview
STERIS is a global leader in infection prevention, sterilization, and surgical support solutions, serving healthcare, pharmaceutical, and life sciences customers. The company generates revenue through three primary segments: Healthcare (sterilization, consumables, and capital equipment for hospitals), Applied Sterilization Technologies (AST, contract sterilization for medical device and pharma clients), and Life Sciences (equipment and consumables for research and manufacturing). STERIS’s business model blends recurring service and consumables with capital equipment sales, providing a mix of stability and cyclical exposure.
Performance Analysis
STERIS delivered 9% revenue growth and 8% constant currency organic growth, signaling robust demand across all major segments. Healthcare, the largest unit, posted 8% organic growth, led by an 11% increase in service revenue and 8% in consumables. Capital equipment revenue rose 7%, supported by a stable backlog exceeding $400 million, though order intake was down 1% year-to-date after a record prior year.
AST achieved 8% organic growth, with services up 9% and capital equipment revenue surging 103%, though the latter created an unfavorable margin mix. Life Sciences grew 5% organically, driven by double-digit consumables growth and 7% capital equipment expansion. Despite top-line strength, gross margin declined 70 basis points to 43.9% and event margin fell 40 basis points to 22.9%, as tariffs and inflation more than offset price and productivity gains. Tariff costs reached $16 million in Q3 and are expected to total $55 million for the year, with the majority impacting Healthcare.
- Service Outperformance: Healthcare and AST service lines continue to deliver above-market growth, helping to stabilize results amid capital equipment cyclicality.
- Margin Compression: Rising input costs, especially tariffs on metals, eroded gross and event margins, despite disciplined operating expense management.
- Cash Flow Strength: Free cash flow improved year-over-year, aided by higher earnings and lower capital spending, supporting a conservative balance sheet with net leverage at 1.2x EBITDA.
While STERIS maintained its full-year outlook, management signaled that margin recovery will depend on ongoing cost mitigation and the ability to offset tariffs through pricing and productivity.
Executive Commentary
"Service continued its streak of outperformance, growing 11% in the third quarter. Consumables also performed well with growth of 8%. Healthcare capital equipment revenue increased 7% for the quarter, with backlog remaining over 400 million."
Dan Correstio, President and Chief Executive Officer
"Positive price and productivity, primarily driven by volume, were more than offset by increased tariffs and inflation. Event margin decreased 40 basis points to 22.9% of revenue compared with last year, mainly driven by the decline in gross margin, which was somewhat mitigated by operating expense discipline."
Karen Burton, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Service-Led Resilience
Recurring service and consumables revenue, which provide stable cash flow, are outpacing capital equipment growth. This recurring base is critical as STERIS manages through capital cycle volatility and input cost shocks, especially in Healthcare and AST.
2. Capital Equipment Backlog and Demand Visibility
Backlogs in Healthcare (> $400 million) and Life Sciences (> $100 million) remain elevated, providing near-term demand visibility. While Healthcare orders are down slightly from a record year, management highlighted that STERIS’s products are viewed as essential “utilities” in hospital capacity planning, supporting resilience even as other medtech peers report capital slowdowns.
3. Margin Protection and Tariff Mitigation
STERIS faces structural margin pressure from tariffs and inflation, particularly on metals used in capital equipment. Management outlined a multi-pronged mitigation strategy: shifting product movement, supplier renegotiations, alternative sourcing, and aggressive cost reduction initiatives. The company is also leveraging pricing power and productivity improvements, but the full offset of tariff impact remains a work in progress.
4. Market Expansion and Regulatory Tailwinds
Shifts in surgical procedures to ambulatory surgery centers (ASC) and ongoing pharma manufacturing onshoring in the U.S. support incremental demand for STERIS’s sterilization and aseptic solutions. Management noted new capacity announcements in key states and highlighted STERIS’s strong positioning in aseptic manufacturing, a core competency.
5. Disciplined Capital Allocation
With net leverage at 1.2x EBITDA, STERIS has capacity for M&A, yet remains disciplined, noting a lack of transformative deals meeting financial and strategic criteria. The company continues to execute smaller product and channel acquisitions, but transformative M&A remains opportunistic.
Key Considerations
STERIS’s Q3 performance reflects a business balancing robust end-market demand with persistent input cost and margin challenges. As the company looks to fiscal 2027, investors should weigh:
Key Considerations:
- Tariff Exposure Escalation: Tariff costs rose $10 million in the quarter, with full-year impact now expected at $55 million, primarily driven by metals in capital equipment.
- Service Growth as a Buffer: Recurring service and consumables demand is offsetting capital equipment order volatility, supporting revenue stability.
- Margin Management Urgency: Cost discipline, productivity, and pricing are critical to protect profitability as inflation and tariffs pressure margins.
- Backlog and Demand Visibility: Strong capital equipment backlogs in Healthcare and Life Sciences provide near-term revenue support, but order intake is normalizing after outsized prior years.
- Disciplined M&A Approach: Ample balance sheet capacity exists, but management is prioritizing strategic fit and return thresholds over deal volume.
Risks
Persistent tariff and inflationary pressures present ongoing risks to margin recovery, especially if further cost pass-through proves difficult or mitigation efforts lag. Capital equipment demand could soften if macro or hospital spending slows, while regulatory changes in healthcare delivery or pharma manufacturing could alter demand patterns. Execution on cost controls and pricing discipline is critical to offset external headwinds and protect earnings growth.
Forward Outlook
For Q4, STERIS guided to:
- Continued high single-digit constant currency organic growth, with caution on sequential slowdown due to tough comps and seasonal patterns
- Ongoing margin pressure as tariff impact persists and service growth moderates
For full-year 2026, management maintained guidance:
- 8-9% reported revenue growth; 7-8% constant currency organic growth
- EPS of $10.15 to $10.30, with upper end less likely due to incremental tariffs
- Free cash flow of $850 million; CapEx of $375 million
Management highlighted several factors that will shape results:
- Tariff cost escalation and mitigation progress
- Service and consumables growth trends in Healthcare and AST
- Capital equipment backlog conversion and order normalization
Takeaways
STERIS is demonstrating revenue resilience and service-driven growth in the face of cost headwinds, but margin compression and tariff exposure remain central risks.
- Margin Recovery Hinges on Cost Actions: Productivity, supplier renegotiations, and alternative sourcing are critical to offset tariff and inflation pressures.
- Service and Consumables Underpin Stability: Recurring revenue streams are supporting results as capital equipment orders normalize from peak levels.
- Watch for 2027 Guidance and Tariff Mitigation: Investors should monitor STERIS’s ability to absorb or pass through tariffs, and any shift in demand as macro or regulatory conditions evolve.
Conclusion
STERIS’s Q3 2026 results highlight a business with strong underlying demand but facing meaningful cost and margin challenges. Execution on cost mitigation and pricing will determine the company’s ability to sustain earnings growth as it enters fiscal 2027.
Industry Read-Through
STERIS’s experience with rising tariffs and inflation underscores a sector-wide challenge for medtech and life sciences suppliers: recurring service and consumables demand can buffer volatility, but margin protection is increasingly dependent on operational agility and supply chain strategy. The resilience of backlogs in essential capital equipment, even as peers report softening, signals ongoing demand for infection prevention and sterilization solutions. Shifts toward ambulatory surgical centers and U.S. pharma onshoring are creating new pockets of growth, but margin headwinds from tariffs and input costs will remain a key theme for the broader healthcare supply chain.